Pharmaceuticals

PROCAPS GROUP S.A.

Procaps Group to Hold Shareholders' Meeting to Discuss Name Change and Financial Statement Revision

PROCAPS GROUP S.A. released FY2023 earnings on September 3 (EST), actual revenue USD 423.75 M (forecast USD 425.1 M), actual EPS USD 0.3994

PROCAPS GROUP S.A. released FY2021 earnings on September 3 Pre-Market (EST), actual revenue USD 403.74 M (forecast USD 411 M), actual EPS USD -1.0901

PROCAPS GROUP S.A. released FY2022 earnings on September 3 Pre-Market (EST), actual revenue USD 403.2 M (forecast USD 415.9 M), actual EPS USD 0.3572

Procaps Group SA reports 5.1% net income growth in 2023 reaching $423.7 million

Starfighters Space

Haoxin

Sidus Space

Mega Fortune

Jyong Biotech

Hycroft Mining

Velo3D

Tradr 2X Long QBTS Daily ETF

Creative Media & Community Trust

Tradr 2X Long FLY Daily ETF

Eli Lilly

Roche

ROCHE HOLDINGS AG

Astrazeneca

NOVARTIS AG

Novo Nordisk AS

Chugai Pharmaceutical

UCB S.A.

Daiichi Sankyo

Otsuka Pharmaceutical

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap